Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension
NCT ID: NCT00060931
Last Updated: 2015-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
501 participants
INTERVENTIONAL
2001-06-30
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metformin Compared to Glyburide in Gestational Diabetes
NCT00965991
A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
NCT00035568
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
NCT00279045
Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial
NCT00629213
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
NCT00698789
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carvedilol
metoprolol
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have a history of mild to moderate hypertension (140-179 systolic blood pressure; 90-1-9 diastolic blood pressure)
* Patients must be on a stable regimen of ACE (angiotensin converting enzyme) / ARB (angiotensin receptor blocker) treatment alone or in combination with other treatments.
* Patients must be on stable antidiabetic regimen (drug treated or diet alone).
* Patient''s laboratory result for HbA1c must be 6.5 - 8.5 (drug treated) or 6.5 - 7.5 (diet alone).
Exclusion Criteria
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Columbia, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Derby, Connecticut, United States
GSK Investigational Site
Farmington, Connecticut, United States
GSK Investigational Site
Hartford, Connecticut, United States
GSK Investigational Site
New Britain, Connecticut, United States
GSK Investigational Site
Newark, Delaware, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Coral Gables, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Fort Meyers, Florida, United States
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Inverness, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Melbourne, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Ocala, Florida, United States
GSK Investigational Site
Ocala, Florida, United States
GSK Investigational Site
Pembroke Pines, Florida, United States
GSK Investigational Site
Saint Petersberg, Florida, United States
GSK Investigational Site
Sarasota, Florida, United States
GSK Investigational Site
Tamarac, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Augusta, Georgia, United States
GSK Investigational Site
Fayetteville, Georgia, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
GSK Investigational Site
Savannah, Georgia, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
West Evanston, Illinois, United States
GSK Investigational Site
Newburgh, Indiana, United States
GSK Investigational Site
Wabash, Indiana, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
Auburn, Maine, United States
GSK Investigational Site
Bangor, Maine, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Ayer, Massachusetts, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Haverhill, Massachusetts, United States
GSK Investigational Site
Springfield, Massachusetts, United States
GSK Investigational Site
Waltham, Massachusetts, United States
GSK Investigational Site
Worcester, Massachusetts, United States
GSK Investigational Site
Worcester, Massachusetts, United States
GSK Investigational Site
Waterford, Michigan, United States
GSK Investigational Site
Gulfport, Mississippi, United States
GSK Investigational Site
Camden, New Jersey, United States
GSK Investigational Site
Hackensack, New Jersey, United States
GSK Investigational Site
Linwood, New Jersey, United States
GSK Investigational Site
Margate City, New Jersey, United States
GSK Investigational Site
Sea Girt, New Jersey, United States
GSK Investigational Site
Voorhees Township, New Jersey, United States
GSK Investigational Site
Buffalo, New York, United States
GSK Investigational Site
Flushing, New York, United States
GSK Investigational Site
Fulton, New York, United States
GSK Investigational Site
Kingston, New York, United States
GSK Investigational Site
Lancaster, New York, United States
GSK Investigational Site
Liverpool, New York, United States
GSK Investigational Site
New Hyde Park, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Scarsdale, New York, United States
GSK Investigational Site
Syracuse, New York, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
Tonawanda, New York, United States
GSK Investigational Site
Williamsville, New York, United States
GSK Investigational Site
Durham, North Carolina, United States
GSK Investigational Site
Hickory, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Statesville, North Carolina, United States
GSK Investigational Site
Wilmington, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Canton, Ohio, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Zanesville, Ohio, United States
GSK Investigational Site
Camp Hill, Pennsylvania, United States
GSK Investigational Site
Connellsville, Pennsylvania, United States
GSK Investigational Site
Downington, Pennsylvania, United States
GSK Investigational Site
Erie, Pennsylvania, United States
GSK Investigational Site
Fleetwood, Pennsylvania, United States
GSK Investigational Site
Morrisville, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Philipsburg, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
West Grove, Pennsylvania, United States
GSK Investigational Site
Columbia, South Carolina, United States
GSK Investigational Site
Greer, South Carolina, United States
GSK Investigational Site
Summerville, South Carolina, United States
GSK Investigational Site
Bristol, Tennessee, United States
GSK Investigational Site
Jackson, Tennessee, United States
GSK Investigational Site
Memphis, Tennessee, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
White River Junction, Utah, United States
GSK Investigational Site
Christiansburg, Virginia, United States
GSK Investigational Site
Falls Church, Virginia, United States
GSK Investigational Site
Fredericksburg, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Salem, Virginia, United States
GSK Investigational Site
Springfield, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
105517/347
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.